API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
Other Suppliers
0
USA (Orange Book)
Europe
Canada
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
Annual Reports
0
0
https://www.ema.europa.eu/documents/product-information/kisplyx-epar-product-information_en.pdf
https://www.biospectrumasia.com/news/25/11929/eisai-msd-start-marketing-activity-for-lenvima.html
https://www.nasdaq.com/press-release/eisai-co-ltd-and-merck-enter-global-strategic-oncology-collaboration-for-lenvima-lenvatinib-mesylate-20180307-01372
https://www.prnewswire.com/news-releases/eisai-and-merck-receive-breakthrough-therapy-designation-from-fda-for-lenvima-lenvatinib-mesylate-and-keytruda-pembrolizumab-as-combination-therapy-for-advanced-andor-metastatic-renal-cell-carcinoma-300579517.html
https://www.pharmacompass.com/pdf/news/eisais-gets-eu-nod-for-cancer-medicine-kisplyx-1479554942.pdf
http://www.biospectrumasia.com/biospectrum/news/224263/eisai-receives-license-indication-anticancer-agent-kisplyx
http://www.biospectrumasia.com/biospectrum/news/224059/eisai-receives-positive-chmp-opinion-indication-anticancer-agent
http://eisai.mediaroom.com/2016-06-02-Eisai-Enters-into-a-Collaboration-Agreement-to-Co-Promote-LENVIMA-Lenvatinib-in-Combination-with-Everolimus-in-the-U-S